# Horimed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/horimed

- Industry: Medical Devices & Equipment
- Headquarters: Tianjin, China
- Website: www.horimedcare.com
- Latest round: Series C (Jan 5, 2023)
- Investors on record: 5

## About

Based in Tianjin, China, and founded in 2016, Horimed Technology Co., Ltd., dba Horimed, operates as a medical device manufacturer, focusing on research and development, production, and sales of optical coherence tomography (OCT) and intravascular ultrasound (IVUS) equipment. The company possesses nearly 100 authorized and pending patents, of which nearly 50 are invention patents. It has established a cooperative relationship with the People's Liberation Army General Hospital, Fuwai Hospital, etc.

In April 2026, Horimed raised over CNY 100 million in venture funding co-led by China International Capital Corporation and Jinkong Qiyuan Capital with participation from Chengdu Science and Technology Venture Capital Group.

Horimed specializes in developing IVUS and OCT devices that are used for pre-procedural lesion assessment and vessel sizing, optimizing stent placement and assessing plaque characterization. The company's main products include IVUS devices and catheters, OCT devices and catheters, VUS/OCT all-in-one dual-catheter systems, IVUS and OCT-based Fractional Flow Reserve (FFR) platforms, etc., aiming to provide integrated pan-vascular solutions based on image-based products for doctors and patients.

The company generates revenue by providing intravascular imaging equipment and related technology-based products and services, including the sales of equipment, catheters, and related technical services.

The company will use the funding raised in April 2026 to further accelerate the research, development, production, and commercialization of vascular interventional endovascular imaging and treatment-related products.

## Funding rounds

- Series C, Jan 5, 2023 — Alibaba Group, Huatai Zijin Investment
- Series C, Jan 7, 2022 — Tasly Capital
- Series B, Nov 22, 2019 — China Everbright
- Series A, Jun 16, 2016 — Zheng Hong Fund Management

## Investors

- Zheng Hong Fund Management (https://capitalatlas.ai/funds/zheng-hong-fund-management) — Series A
- China Everbright (https://capitalatlas.ai/funds/china-everbright) — Series B
- Tasly Capital — Series C
- Alibaba Group — Series C
- Huatai Zijin Investment (https://capitalatlas.ai/funds/huatai-zijin-investment) — Series C